SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2010 financial results on Wednesday, May 5, 2010, following the close of market. Ligand’s President and CEO, John L. Higgins and Vice President of Finance and CFO, John Sharp will host the conference call.
First Quarter Earnings Call
|What:||Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates.|
|When:||Wednesday, May 5, 2010|
|Time:||1:30 p.m. Pacific time (4:30 p.m. Eastern time)|
Conference call and replay accessible at www.ligand.com.
|Conference Call:||(877) 407-4019, passcode: Ligand|
|(201) 689-8337 outside the U.S.|
|Replay:||(877) 660-6853, Account #: 361 passcode: 349820|
|(201) 612-7415 outside the U.S.|
About Ligand Pharmaceuticals
Ligand discovers and develops new drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's, inflammatory diseases, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Bristol-Myers Squibb, and Cephalon and more than 30 programs are in various stages of development by its partners.
Ligand Pharmaceuticals Incorporated
John L. Higgins, President and CEO
Erika Luib, Investor Relations
Lippert/Heilshorn & Associates
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical